Join Chantal & Max on Thursday 10th October at 14:00 BST / 15:00 CEST / 09:00 EDT for the latest episode in our webinar series on the upcoming European Health Technology Assessment (HTA) regulation.
Building on the success of our previous webinar, 'EU HTA Regulation: What's Changing and Why It Matters,' this 60-minute session will focus on the strategic implications of the new EU HTA regulation, offering the latest updates and essential advice for Drug Development Leaders.
Why you should attend
This webinar is designed for those looking to:
- Stay ahead of recent updates and developments in EU HTA regulation
- Address common industry concern and frequently asked questions
- Explore strategic approaches for clinical development and market access
- Optimize resources for regulatory and HTA processes
- Manage potential discrepancies between regulatory and HTA evidence requirements
Our conversational format will allow Chantal & Max to address real concerns and questions based on feedback from clients and other industry leaders.
